Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 193

1.

Cytomegalovirus viremia associated with increased mortality in cryptococcal meningitis in sub-Saharan Africa.

Skipper CP, Schleiss MR, Bangdiwala AS, Hernandez-Alvarado N, Taseera K, Nabeta HW, Musubire AK, Lofgren SM, Wiesner DL, Rhein J, Rajasingham R, Schutz C, Meintjes G, Muzoora C, Meya DB, Boulware DR; COAT Team.

Clin Infect Dis. 2019 Sep 1. pii: ciz864. doi: 10.1093/cid/ciz864. [Epub ahead of print]

PMID:
31504335
2.

Short course amphotericin B in addition to sertraline and fluconazole for treatment of HIV-associated cryptococcal meningitis in rural Tanzania.

Katende A, Mbwanji G, Faini D, Nyuri A, Kalinjuma AV, Mnzava D, Hullsiek KH, Rhein J, Weisser M, Meya DB, Boulware DR, Letang E; KIULARCO Study Group.

Mycoses. 2019 Aug 28. doi: 10.1111/myc.12995. [Epub ahead of print]

PMID:
31461550
3.

Minimum Inhibitory Concentration Distribution of Fluconazole against Cryptococcus Species and the Fluconazole Exposure Prediction Model.

Chesdachai S, Rajasingham R, Nicol MR, Meya DB, Bongomin F, Abassi M, Skipper C, Kwizera R, Rhein J, Boulware DR.

Open Forum Infect Dis. 2019 Aug 17. pii: ofz369. doi: 10.1093/ofid/ofz369. [Epub ahead of print]

PMID:
31420668
4.

Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial.

Rhein J, Huppler Hullsiek K, Tugume L, Nuwagira E, Mpoza E, Evans EE, Kiggundu R, Pastick KA, Ssebambulidde K, Akampurira A, Williams DA, Bangdiwala AS, Abassi M, Musubire AK, Nicol MR, Muzoora C, Meya DB, Boulware DR; ASTRO-CM team.

Lancet Infect Dis. 2019 Aug;19(8):843-851. doi: 10.1016/S1473-3099(19)30127-6.

PMID:
31345462
5.

Diagnosis and Management of Central Nervous System Cryptococcal Infections in HIV-Infected Adults.

Skipper C, Abassi M, Boulware DR.

J Fungi (Basel). 2019 Jul 19;5(3). pii: E65. doi: 10.3390/jof5030065. Review.

6.

Longitudinal Changes in Cd4+, Cd8+ T Cell Phenotype and Activation Marker Expression Following Antiretroviral Therapy Initiation among Patients with Cryptococcal Meningitis.

Bayiyana A, Okurut S, Nabatanzi R, Zziwa G, Boulware DR, Lutwama F, Meya D.

J Fungi (Basel). 2019 Jul 17;5(3). pii: E63. doi: 10.3390/jof5030063.

7.

Identification of Pathogen Genomic Differences That Impact Human Immune Response and Disease during Cryptococcus neoformans Infection.

Gerstein AC, Jackson KM, McDonald TR, Wang Y, Lueck BD, Bohjanen S, Smith KD, Akampurira A, Meya DB, Xue C, Boulware DR, Nielsen K.

MBio. 2019 Jul 16;10(4). pii: e01440-19. doi: 10.1128/mBio.01440-19.

8.

Management of amphotericin-induced phlebitis among HIV patients with cryptococcal meningitis in a resource-limited setting: a prospective cohort study.

Ahimbisibwe C, Kwizera R, Ndyetukira JF, Kugonza F, Sadiq A, Hullsiek KH, Williams DA, Rhein J, Boulware DR, Meya DB.

BMC Infect Dis. 2019 Jun 26;19(1):558. doi: 10.1186/s12879-019-4209-7.

9.

Heterogeneity in neurocognitive change trajectories among people with HIV starting antiretroviral therapy in Rakai, Uganda.

Rubin LH, Saylor D, Nakigozi G, Nakasujja N, Robertson K, Kisakye A, Batte J, Mayanja R, Anok A, Lofgren SM, Boulware DR, Dastgheyb R, Reynolds SJ, Quinn TC, Gray RH, Wawer MJ, Sacktor N.

J Neurovirol. 2019 Jun 19. doi: 10.1007/s13365-019-00768-5. [Epub ahead of print]

PMID:
31218522
10.

Cerebrospinal Fluid and Brain Tissue Penetration of Tenofovir, Lamivudine, and Efavirenz in Postmortem Tissues with Cryptococcal Meningitis.

Nicol MR, Pastick KA, Taylor J, Namuju OC, Rhein J, Williams DA, Meya DB, Boulware DR, Lukande R.

Clin Transl Sci. 2019 Sep;12(5):445-449. doi: 10.1111/cts.12661. Epub 2019 Jul 10.

11.

Cryptococcal antigen screening and preemptive treatment - how can we improve survival?

Rajasingham R, Boulware DR.

Clin Infect Dis. 2019 Jun 8. pii: ciz488. doi: 10.1093/cid/ciz488. [Epub ahead of print] No abstract available.

PMID:
31179484
12.

Essential in vitro diagnostics for advanced HIV and serious fungal diseases: international experts' consensus recommendations.

Bongomin F, Govender NP, Chakrabarti A, Robert-Gangneux F, Boulware DR, Zafar A, Oladele RO, Richardson MD, Gangneux JP, Alastruey-Izquierdo A, Bazira J, Boyles TH, Sarcarlal J, Nacher M, Obayashi T, Worodria W, Pasqualotto AC, Meya DB, Cheng B, Sriruttan C, Muzoora C, Kambugu A, Rodriguez Tudela JL, Jordan A, Chiller TM, Denning DW.

Eur J Clin Microbiol Infect Dis. 2019 Sep;38(9):1581-1584. doi: 10.1007/s10096-019-03600-4. No abstract available.

PMID:
31175479
13.

HIV-Associated Cryptococcal Immune Reconstitution Inflammatory Syndrome Is Associated with Aberrant T Cell Function and Increased Cytokine Responses.

Meya DB, Okurut S, Zziwa G, Cose S, Boulware DR, Janoff EN.

J Fungi (Basel). 2019 May 23;5(2). pii: E42. doi: 10.3390/jof5020042.

14.

Change in plasma CrAg titer is not associated with survival among HIV-infected persons receiving preemptive therapy for asymptomatic cryptococcal antigenemia.

Pullen MF, Kakooza F, Nalintya E, Kiragga AN, Morawski BM, Rajasingham R, Mubiru A, Manabe YC, Kaplan JE, Meya DB, Boulware DR; ORCAS study team.

Clin Infect Dis. 2019 May 22. pii: ciz418. doi: 10.1093/cid/ciz418. [Epub ahead of print] No abstract available.

PMID:
31119280
15.

Inadequate diagnostics: the case to move beyond the bacilli for detection of meningitis due to Mycobacterium tuberculosis.

Bahr NC, Meintjes G, Boulware DR.

J Med Microbiol. 2019 May;68(5):755-760. doi: 10.1099/jmm.0.000975. Epub 2019 Apr 17.

PMID:
30994435
16.

Tuberculosis at the animal-human interface in the Ugandan cattle corridor using a third-generation sequencing platform: a cross-sectional analysis study.

Pullen MF, Boulware DR, Sreevatsan S, Bazira J.

BMJ Open. 2019 Apr 8;9(4):e024221. doi: 10.1136/bmjopen-2018-024221.

17.

AMBIsome Therapy Induction OptimisatioN (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: economic evaluation protocol for a randomised controlled trial-based equivalence study.

Ponatshego PL, Lawrence DS, Youssouf N, Molloy SF, Alufandika M, Bango F, Boulware DR, Chawinga C, Dziwani E, Gondwe E, Hlupeni A, Hosseinipour MC, Kanyama C, Meya DB, Mosepele M, Muthoga C, Muzoora CK, Mwandumba H, Ndhlovu CE, Rajasingham R, Sayed S, Shamu S, Tsholo K, Tugume L, Williams D, Maheswaran H, Shiri T, Boyer-Chammard T, Loyse A, Chen T, Wang D, Lortholary O, Lalloo DG, Meintjes G, Jaffar S, Harrison TS, Jarvis JN, Niessen LW.

BMJ Open. 2019 Apr 1;9(4):e026288. doi: 10.1136/bmjopen-2018-026288.

18.

Xpert MTB/RIF Ultra for Tuberculosis Testing in Children: A Mini-Review and Commentary.

Atherton RR, Cresswell FV, Ellis J, Kitaka SB, Boulware DR.

Front Pediatr. 2019 Feb 28;7:34. doi: 10.3389/fped.2019.00034. eCollection 2019. Review.

19.

The Mouse Inhalation Model of Cryptococcus neoformans Infection Recapitulates Strain Virulence in Humans and Shows that Closely Related Strains Can Possess Differential Virulence.

Mukaremera L, McDonald TR, Nielsen JN, Molenaar CJ, Akampurira A, Schutz C, Taseera K, Muzoora C, Meintjes G, Meya DB, Boulware DR, Nielsen K.

Infect Immun. 2019 Apr 23;87(5). pii: e00046-19. doi: 10.1128/IAI.00046-19. Print 2019 Mar.

PMID:
30833336
20.

New FDA approvals decrease generic flucytosine costs.

Rajasingham R, Boulware DR.

Clin Infect Dis. 2019 Jan 29. doi: 10.1093/cid/ciz037. [Epub ahead of print] No abstract available.

PMID:
30698690
21.

Case Report: Three's a crowd: a case report examining the diagnostic and pharmacokinetic challenges in HIV-tuberculous meningitis-malaria co-infection.

Ellis J, Eneh PC, Ssebambulidde K, Rutakingirwa MK, Lamorde M, Rhein J, Cresswell FV, Boulware DR, Nicol MR.

Version 2. Wellcome Open Res. 2019 Jan 15 [revised 2019 Jan 1];3:111. doi: 10.12688/wellcomeopenres.14726.2. eCollection 2018.

22.

Epidemiology of non-traumatic spinal cord injury in Uganda: a single center, prospective study with MRI evaluation.

Musubire AK, Meya DB, Katabira ET, Meyer ACL, Bohjanen PR, Boulware DR, Minja F.

BMC Neurol. 2019 Jan 15;19(1):10. doi: 10.1186/s12883-019-1236-3.

23.

Correction to: AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial.

Lawrence DS, Youssouf N, Molloy SF, Alanio A, Alufandika M, Boulware DR, Boyer-Chammard T, Chen T, Dromer F, Hlupeni A, Hope W, Hosseinipour MC, Kanyama C, Lortholary O, Loyse A, Meya DB, Mosepele M, Muzoora C, Mwandumba HC, Ndhlovu CE, Niessen L, Schutz C, Stott KE, Wang D, Lalloo DG, Meintjes G, Jaffar S, Harrison TS, Jarvis JN.

Trials. 2019 Jan 14;20(1):48. doi: 10.1186/s13063-018-3155-9.

24.

Evaluation of a national cryptococcal antigen screening program for HIV-infected patients in Uganda: A cost-effectiveness modeling analysis.

Rajasingham R, Meya DB, Greene GS, Jordan A, Nakawuka M, Chiller TM, Boulware DR, Larson BA.

PLoS One. 2019 Jan 10;14(1):e0210105. doi: 10.1371/journal.pone.0210105. eCollection 2019.

25.

Blood neutrophil counts in HIV-infected patients with cryptococcal meningitis: Association with mortality.

Musubire AK, Meya DB, Rhein J, Meintjes G, Bohjanen PR, Nuwagira E, Muzoora C, Boulware DR, Hullsiek KH; COAT and ASTRO trial teams.

PLoS One. 2018 Dec 31;13(12):e0209337. doi: 10.1371/journal.pone.0209337. eCollection 2018.

26.

Cryptococcal meningitis is a cause for cross-reactivity in cerebrospinal fluid assays for anti-Histoplasma, anti-Coccidioides and anti-Blastomyces antibodies.

Bahr NC, Panackal AA, Durkin MM, Smedema ML, Keown W, Davis TE, Raymond-Guillen L, Park YD, Marr KA, Fries BC, Williamson PR, Boulware DR, Wheat LJ.

Mycoses. 2019 Mar;62(3):268-273. doi: 10.1111/myc.12882. Epub 2019 Jan 1.

PMID:
30565753
27.

Detection of Cryptococcus DNA by Metagenomic Next-generation Sequencing in Symptomatic Cryptococcal Antigenemia.

Ramachandran PS, Cresswell FV, Meya DB, Langelier C, Crawford ED, DeRisi JL, Boulware DR, Wilson MR.

Clin Infect Dis. 2019 May 17;68(11):1978-1979. doi: 10.1093/cid/ciy1024. No abstract available.

PMID:
30535266
28.

AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial.

Lawrence DS, Youssouf N, Molloy SF, Alanio A, Alufandika M, Boulware DR, Boyer-Chammard T, Chen T, Dromer F, Hlupeni A, Hope W, Hosseinipour MC, Kanyama C, Lortholary O, Loyse A, Meya DB, Mosepele M, Muzoora C, Mwandumba HC, Ndhlovu CE, Niessen L, Schutz C, Stott KE, Wang D, Lalloo DG, Meintjes G, Jaffar S, Harrison TS, Jarvis JN.

Trials. 2018 Nov 23;19(1):649. doi: 10.1186/s13063-018-3026-4. Erratum in: Trials. 2019 Jan 14;20(1):48.

29.

Laboratory-Reflex Cryptococcal Antigen Screening Is Associated With a Survival Benefit in Tanzania.

Faini D, Kalinjuma AV, Katende A, Mbwaji G, Mnzava D, Nyuri A, Glass TR, Furrer H, Hatz C, Boulware DR, Letang E.

J Acquir Immune Defic Syndr. 2019 Feb 1;80(2):205-213. doi: 10.1097/QAI.0000000000001899.

30.

Reflexive Laboratory-Based Cryptococcal Antigen Screening and Preemptive Fluconazole Therapy for Cryptococcal Antigenemia in HIV-Infected Individuals With CD4 <100 Cells/µL: A Stepped-Wedge, Cluster-Randomized Trial.

Meya DB, Kiragga AN, Nalintya E, Morawski BM, Rajasingham R, Park BJ, Mubiru A, Kaplan JE, Manabe YC, Boulware DR.

J Acquir Immune Defic Syndr. 2019 Feb 1;80(2):182-189. doi: 10.1097/QAI.0000000000001894.

31.

Ophthalmic signs in Ugandan adults with HIV-associated cryptococcal meningitis: A nested analysis of the ASTRO-CM cohort.

Atherton RR, Ellis J, Cresswell FV, Rhein J, Boulware DR.

Version 2. Wellcome Open Res. 2018 Oct 12 [revised 2018 Jan 1];3:80. doi: 10.12688/wellcomeopenres.14666.2. eCollection 2018.

32.

Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries.

Loyse A, Burry J, Cohn J, Ford N, Chiller T, Ribeiro I, Koulla-Shiro S, Mghamba J, Ramadhani A, Nyirenda R, Aliyu SH, Wilson D, Le T, Oladele R, Lesikari S, Muzoora C, Kalata N, Temfack E, Mapoure Y, Sini V, Chanda D, Shimwela M, Lakhi S, Ngoma J, Gondwe-Chunda L, Perfect C, Shroufi A, Andrieux-Meyer I, Chan A, Schutz C, Hosseinipour M, Van der Horst C, Klausner JD, Boulware DR, Heyderman R, Lalloo D, Day J, Jarvis JN, Rodrigues M, Jaffar S, Denning D, Migone C, Doherty M, Lortholary O, Dromer F, Stack M, Molloy SF, Bicanic T, van Oosterhout J, Mwaba P, Kanyama C, Kouanfack C, Mfinanga S, Govender N, Harrison TS.

Lancet Infect Dis. 2019 Apr;19(4):e143-e147. doi: 10.1016/S1473-3099(18)30493-6. Epub 2018 Oct 18. Review.

PMID:
30344084
33.

HIV-Associated Cryptococcal Meningitis Occurring at Relatively Higher CD4 Counts.

Tugume L, Rhein J, Hullsiek KH, Mpoza E, Kiggundu R, Ssebambulidde K, Schutz C, Taseera K, Williams DA, Abassi M, Muzoora C, Musubire AK, Meintjes G, Meya DB, Boulware DR; COAT and ASTRO-CM teams .

J Infect Dis. 2019 Feb 23;219(6):877-883. doi: 10.1093/infdis/jiy602.

PMID:
30325463
34.

Cryptococcal Meningitis Diagnostics and Screening in the Era of Point-of-Care Laboratory Testing.

Rajasingham R, Wake RM, Beyene T, Katende A, Letang E, Boulware DR.

J Clin Microbiol. 2019 Jan 2;57(1). pii: e01238-18. doi: 10.1128/JCM.01238-18. Print 2019 Jan. Review.

35.

Symptomatic Cryptococcal Antigenemia Presenting as Early Cryptococcal Meningitis With Negative Cerebral Spinal Fluid Analysis.

Ssebambulidde K, Bangdiwala AS, Kwizera R, Kandole TK, Tugume L, Kiggundu R, Mpoza E, Nuwagira E, Williams DA, Lofgren SM, Abassi M, Musubire AK, Cresswell FV, Rhein J, Muzoora C, Hullsiek KH, Boulware DR, Meya DB; Adjunctive Sertraline for Treatment of HIV-associated Cryptococcal Meningitis Team .

Clin Infect Dis. 2019 May 30;68(12):2094-2098. doi: 10.1093/cid/ciy817.

PMID:
30256903
36.

Cryptococcal Meningitis and Tuberculous Meningitis Co-infection in HIV-Infected Ugandan Adults.

Ellis J, Cresswell FV, Rhein J, Ssebambulidde K, Boulware DR.

Open Forum Infect Dis. 2018 Aug 29;5(8):ofy193. doi: 10.1093/ofid/ofy193. eCollection 2018 Aug. Erratum in: Open Forum Infect Dis. 2018 Oct 16;6(3):ofy252.

37.

High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study).

Cresswell FV, Ssebambulidde K, Grint D, Te Brake L, Musabire A, Atherton RR, Tugume L, Muzoora C, Lukande R, Lamorde M, Aarnoutse R, Meya D, Boulware DR, Elliott AM.

Wellcome Open Res. 2018 Jul 10;3:83. doi: 10.12688/wellcomeopenres.14691.1. eCollection 2018.

38.

Detrimental Outcomes of Unmasking Cryptococcal Meningitis With Recent ART Initiation.

Rhein J, Hullsiek KH, Evans EE, Tugume L, Nuwagira E, Ssebambulidde K, Kiggundu R, Mpoza E, Musubire AK, Bangdiwala AS, Bahr NC, Williams DA, Abassi M, Muzoora C, Meya DB, Boulware DR; ASTRO-CM study team .

Open Forum Infect Dis. 2018 May 24;5(8):ofy122. doi: 10.1093/ofid/ofy122. eCollection 2018 Aug.

39.

A qualitative evaluation of an implementation study for cryptococcal antigen screening and treatment in Uganda.

Lofgren SM, Nalintya E, Meya DB, Boulware DR, Rajasingham R.

Medicine (Baltimore). 2018 Aug;97(31):e11722. doi: 10.1097/MD.0000000000011722.

40.

Detection of Mycobacterium tuberculosis in urine by Xpert MTB/RIF Ultra: A useful adjunctive diagnostic tool in HIV-associated tuberculosis.

Atherton RR, Cresswell FV, Ellis J, Skipper C, Tadeo KK, Mugumya G, Wadda V, Meya DB, Boulware DR.

Int J Infect Dis. 2018 Oct;75:92-94. doi: 10.1016/j.ijid.2018.07.007. Epub 2018 Jul 19.

41.

Can improved diagnostics reduce mortality from Tuberculous meningitis? Findings from a 6.5-year cohort in Uganda.

Cresswell FV, Bangdiwala AS, Bahr NC, Trautner E, Nuwagira E, Ellis J, Rajasingham R, Rhein J, Williams DA, Muzoora C, Elliott AM, Meya DB, Boulware DR.

Wellcome Open Res. 2018 May 29;3:64. doi: 10.12688/wellcomeopenres.14610.2. eCollection 2018.

42.

Cerebral Oximetry for Detecting High-mortality Risk Patients with Cryptococcal Meningitis.

Diehl JW, Hullsiek KH, Okirwoth M, Stephens N, Abassi M, Rhein J, Meya DB, Boulware DR, Musubire AK; ASTRO-CM Trial Team .

Open Forum Infect Dis. 2018 May 8;5(6):ofy105. doi: 10.1093/ofid/ofy105. eCollection 2018 Jun 1.

43.

Etiology of Sepsis in Uganda Using a Quantitative Polymerase Chain Reaction-based TaqMan Array Card.

Moore CC, Jacob ST, Banura P, Zhang J, Stroup S, Boulware DR, Scheld WM, Houpt ER, Liu J.

Clin Infect Dis. 2019 Jan 7;68(2):266-272. doi: 10.1093/cid/ciy472.

44.

Xpert MTB/RIF® assay for the diagnosis of HIV-related tuberculous meningitis in São Paulo, Brazil.

Azevedo RG, Dinallo FS, de Laurentis LS, Boulware DR, Vidal JE.

Int J Tuberc Lung Dis. 2018 Jun 1;22(6):706-707. doi: 10.5588/ijtld.18.0191. No abstract available.

45.

Delta-like 1 protein, vitamin D binding protein and fetuin for detection of Mycobacterium tuberculosis meningitis.

Bahr NC, Halupnick R, Linder G, Kiggundu R, Nabeta HW, Williams DA, Musubire AK, Morawski BM, Sreevatsan S, Meya DB, Rhein J, Boulware DR.

Biomark Med. 2018 Jul;12(7):707-716. doi: 10.2217/bmm-2017-0373. Epub 2018 Jun 1.

46.

A Prospective Evaluation of a Multisite Cryptococcal Screening and Treatment Program in HIV Clinics in Uganda.

Nalintya E, Meya DB, Lofgren S, Huppler Hullsiek K, Boulware DR, Rajasingham R.

J Acquir Immune Defic Syndr. 2018 Jun 1;78(2):231-238. doi: 10.1097/QAI.0000000000001669.

47.

Xpert Ultra's place in the diagnosis of tuberculous meningitis - Authors' reply.

Bahr NC, Boulware DR, Cresswell FV.

Lancet Infect Dis. 2018 Mar;18(3):249-250. doi: 10.1016/S1473-3099(18)30078-1. No abstract available.

48.

Performance of cryptococcal antigen lateral flow assay in serum, cerebrospinal fluid, whole blood, and urine in HIV-infected patients with culture-proven cryptococcal meningitis admitted at a Brazilian referral center.

Vidal JE, Toniolo C, Paulino A, Colombo AL, Martins MDA, Meira CDS, Azevedo RGS, Pereira-Chioccola VL, Gomes HR, Lazera MDS, Oliveira ACP, Boulware DR.

Rev Inst Med Trop Sao Paulo. 2018;60:e1. doi: 10.1590/s1678-9946201860001. Epub 2018 Feb 15.

49.

Evaluation of trypan blue stain in the TC20 automated cell counter as a point-of-care for the enumeration of viable cryptococcal cells in cerebrospinal fluid.

Kwizera R, Akampurira A, Kandole TK, Nabaggala MS, Williams DA, Kambugu A, Meya DB, Rhein J, Boulware DR; ASTRO Team.

Med Mycol. 2018 Jul 1;56(5):559-564. doi: 10.1093/mmy/myx076.

50.

Absence of cerebrospinal fluid pleocytosis in tuberculous meningitis is a common occurrence in HIV co-infection and a predictor of poor outcomes.

Cresswell FV, Bangdiwala AS, Meya DB, Bahr NC, Vidal JE, Török ME, Thao LTP, Thwaites GE, Boulware DR.

Int J Infect Dis. 2018 Mar;68:77-78. doi: 10.1016/j.ijid.2018.01.014. Epub 2018 Jan 31. No abstract available.

Supplemental Content

Loading ...
Support Center